TG Therapeutics to Participate in the B. Riley Securities Neuroscience Conference
Fireside chat scheduled for Wednesday, April 28, 2021 at 9:00 AM ET
Get Alerts TGTX Hot Sheet
Join SI Premium – FREE
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities Neuroscience Conference being held virtually. The fireside chat is scheduled to take place on Wednesday, April 28, 2021 at 9:00 AM ET.
A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG’s website following the event.
ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ™ (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.UKONIQ™ is a trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations Email: [email protected]Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations: Email: [email protected] Telephone: 1.877.575.TGTX (8489), Option 6
Source: TG Therapeutics, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bitcoin Japan Builds the Brand Behind Its AI and Robotics Strategy
- Bavarian Nordic Upgrades its Full-Year 2026 Financial Guidance
- Micware Presents Research Results at the International Conference “IEEE IV 2026”
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
B. Riley, Twitter, Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share